Clinical trials for Alzheimer’s disease have predominantly focused on individuals who have already developed symptoms. However, in the last few years, researchers have initiated trials at a much earlier stage of the disease course when brain pathology hasn’t yet appeared (primary prevention trials).
At the Wolfson Closing Symposium (19 June 2019, University College London, UK), we spoke with Randall Bateman (Washington University, MO, USA) to discover more about these prevention trials in Alzheimer’s disease, including what primary prevention trials are telling us so far and what the main challenges surrounding such trials are.
Interview questions on prevention trials in Alzheimer’s disease:
00:21 – What primary prevention trials are ongoing for Alzheimer’s disease and what are they telling us so far?
02:02 – There has been a lot of traction around whether the amyloid hypothesis should still be the way forward when considering primary prevention treatment. In your opinion, should researchers be exploring alternative avenues to amyloid-β?
03:45 – What are the main challenges surrounding primary prevention trials for Alzheimer’s?
04:52 – Looking forward, where do you anticipate the field will be in 5–10 years’ time?
You might also like: